# Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

> **NCT03064074** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **DRUG:** Fresolimumab

## Key facts

- **NCT ID:** NCT03064074
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2022-07-04
- **Final completion:** 2022-07-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03064074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03064074, "Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03064074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*